dornase alfa dry powder (MNKD-301) / MannKind - LARVOL DELTA

Inhalable dry powder formulations of the commercialized form of Deoxyribonuclease I - a dried alternative for the treatment of cystic fibrosis. (PubMed, Eur J Pharm Sci) - "The resulting spray-dried powders demonstrated suitable in vitro aerosolisation characteristics suitable for pulmonary delivery, with enzymatic activity retention of up to 94%. In vitro tests on the most promising formulation showed no cell toxicity, supporting its potential for pulmonary delivery, as a patient-friendly alternative for CF therapy."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases